Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $436,809.10 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 14,609 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10. Following the transaction, the chief marketing officer directly owned 14,609 shares of the company’s stock, valued at approximately $436,809.10. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, May 14th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00.

Maze Therapeutics Trading Up 4.9%

Shares of Maze Therapeutics stock traded up $1.45 on Thursday, reaching $31.26. The company had a trading volume of 575,498 shares, compared to its average volume of 717,789. The firm’s 50 day moving average price is $25.81 and its two-hundred day moving average price is $35.73. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. Maze Therapeutics, Inc. has a 52-week low of $10.98 and a 52-week high of $53.65. The firm has a market cap of $1.73 billion, a PE ratio of -12.36 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. Sell-side analysts predict that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Maze Therapeutics

Large investors have recently modified their holdings of the company. Royal Bank of Canada grew its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Maze Therapeutics during the 4th quarter worth $39,000. Ameritas Investment Partners Inc. grew its position in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics in the fourth quarter valued at $43,000. Finally, Russell Investments Group Ltd. increased its stake in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on MAZE shares. Wedbush lifted their target price on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. HC Wainwright raised their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Truist Financial dropped their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.